India, May 8 -- Amid concerns over Thrombosis (blood clotting) and Thrombocytopenia Syndrome (low platelet count), or TTS, rare complications associated with Covishield, the vaccine administered to protect against Covid-19, Pune-based Serum Institute of India (SII), which manufactured the vaccine in association with British pharma giant AstraZeneca, stated on Wednesday that it had disclosed its side-effects, including TTS, in the packaging insert in 2021.

Laying emphasis on safety as a priority, the company also highlighted Covishield's role in saving millions of lives globally.

SII's statement coincides with AstraZeneca's battle against numerous lawsuits in the United Kingdom, after a patient alleged a permanent brain injury due to a b...